<DOC>
	<DOCNO>NCT00254865</DOCNO>
	<brief_summary>The objective study compare level hormone norelgestromin , norgestrel , ethinyl estradiol bloodstream healthy female volunteer administer ORTHO EVRAÂ® ( transdermal contraceptive patch ) CILESTÂ® ( oral contraceptive ) . The open-label treatment phase study consist two 28-day cycle one treatment , washout period 28 day , crossover two 28-day cycle treatment .</brief_summary>
	<brief_title>A Comparative Pharmacokinetic Study ORTHO EVRA ( Transdermal Contraceptive Patch ) CILEST ( Oral Contraceptive ) Healthy Female Volunteers</brief_title>
	<detailed_description>ORTHO EVRA® combination , monophasic transdermal contraceptive patch contain 6 mg norelgestromin ( NGMN ) 0.75 mg ethinyl estradiol ( EE ) , deliver systemic circulation average 150 µg/day NGMN 20 µg/day EE . CILEST® oral contraceptive tablet contain 250 µg norgestimate ( NGM ) 35 µg ethinyl estradiol ( EE ) . Although multiple-dose pharmacokinetics active serum progestin estrogen analytes follow administration ORTHO EVRA® formulation OrthoCyclen ( CILEST® ) evaluate previously separate study , multiple dose pharmacokinetics evaluate comparative manner single study . The present study design directly compare total exposure pharmacokinetics , comparable time interval ( Week 1 Cycle 1 Week 3 Cycle 2 ) , NGMN , NG , EE ORTHO EVRA® CILEST® single study , design randomize , crossover study . Since EVRA® wear 7 day CILEST® once-daily tablet , pharmacokinetics estimate different time period ORTHO EVRA® ( 7 day ) CILEST® ( Days 1 and/or 7 7 day period ) cycle . Pharmacodynamic parameter estrogenicity determine compare assist interpretation pharmacokinetic data . This single center , randomize , open-label , two-way crossover , pharmacokinetic study ORTHO EVRA® CILEST® . The subject population comprise 32 healthy female volunteer age 18 48 year body mass index ( BMI ) 18.0 29.9 kg per meter square . The study consist pretreatment phase ( screen period 21 day ) , open-label treatment phase ( two 28-day cycle 1 treatment , washout period 28 day , cross-over two 28-day cycle treatment ) , post-treatment phase ( follow-up early withdrawal visit ) . Treatment Day 1 first day menses , within 5 day first day menses . In one treatment period , subject wear ORTHO EVRA® patch abdomen buttock ( base randomization schedule ) apply weekly 3 consecutive week two 28-day cycle . ORTHO EVRA® apply remove investigator ( designate study personnel ) , Days 1 ( application ) , 8 , 15 , 22 ( removal ) cycle . In treatment period , subject take CILEST® tablet daily first 21 day cycle two 28-day cycle . CILEST tablet administer subject 225 mL ( 7.5 oz ) water investigator designate personnel Days 1 8 Cycle 1 Days 18 21 Cycle 2 . On day subject require study unit , subject self-dose home ( Days 9 21 Cycle 1 Days 1 17 Cycle 2 ) . Neither ORTHO EVRA® patch CILEST® tablet use Days 22 28 ( 4th week ) cycle , subject may experience withdrawal bleeding . The total duration open-label treatment phase approximately 5 month . The primary outcome study comparison total exposure pharmacokinetics , base comparable interval , NGMN , NG , EE . Blood sample draw Week 1 Cycle 1 Week 3 Cycle 2 analysis plasma NGMN ( total anti syn isomer ) , NG , EE concentration . Pharmacokinetic parameter , Cmax , tmax , AUC estimate non-compartmental method . Safety assess monitor incidence severity adverse event report , clinical laboratory test , vital sign , physical gynecological examination electrocardiogram ( ECG ) . The expectation ratios exposure product ratios NG/NGMN product similar . However , confidence interval around ratio require fall within 80-125 % . Treatment 1 : ORTHO EVRA® transdermal patch , apply weekly 3 consecutive week cycle two 28-day cycle . Treatment 2 : CILEST® tablet , take daily mouth 21 consecutive day cycle , two 28-day cycle . There 28-day washout treatment .</detailed_description>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Subjects pregnant ( demonstrated pregnancy test screen admission ) breast feeding , complete last term pregnancy least 60 day admission visit confirm good health determine medical history , physical examination ( include vital sign ) , gynecologic examination ( include breast pelvic exam ) , laboratory test result , absence evidence cervical dysplasia ( document Pap smear within 6 month dose ) history regular menstrual cycle , weigh least 121 pound ( 55 kilogram ) , body mass index ( BMI ) 18.0 29.9 kg per meter square , hematocrit least 36 % nonsmoker use tobacco product least 6 month study admission Agree use prescription nonprescription medication duration study , surgically sterile , agree use spermicide barrier contraception , nonsteroidcontaining intrauterine device method contraception participation study Subjects history presence disorder commonly accept contraindication sex hormonal therapy include , limited : deep vein thrombophlebitis thromboembolic disorder , cerebral vascular coronary artery disease , chronic untreated hypertension migraine , benign malignant liver tumor develop use oral contraceptive estrogencontaining product , know suspected estrogendependent neoplasia presence disorder commonly accept contraindication combine oral contraceptive therapy include , limited : undiagnosed abnormal vaginal bleeding , neurovascular lesion eye serious visual disturbance , impairment liver function liver disease , kidney disease recent history ( within 12 month admission visit ) alcohol substance abuse use steroidhormonal therapy within 30 day study admission , receive Depo Provera® injection within 6 month study admission , currently Norplant® place , removal Norplant within 60 day study admission , use steroid hormonecontaining intrauterine device ( IUD ) within 3 month study admission elevate blood pressure ( sit systolic BP &gt; 140 mm Hg diastolic BP &gt; 90 mm Hg ) history presence hypersensitivity response topical application ( bandage , surgical tape , etc . ) active inflammation skin ( dermatitis ) skin condition ( dermatosis ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Transdermal contraception</keyword>
	<keyword>contraceptive</keyword>
	<keyword>hormonal , steroid contraception</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>progesterone</keyword>
	<keyword>EVRA</keyword>
	<keyword>CILEST</keyword>
</DOC>